The University of Texas MD Anderson Cancer Center, Houston, TX — Houston, Texas

The University of Texas MD Anderson Cancer Center, Houston, TX is a clinical research site located in Houston, Texas, United States 77030.

Crixeo Clinical Trials Trust Score: 82/100 (GOOD). This profile has not yet been claimed by the site owner.

The University of Texas MD Anderson Cancer Center, Houston, TX has participated in 1 clinical trials.

Therapeutic areas: Acute Myeloid Leukaemia.

Sponsors: Institut de Recherches Internationales Servier.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Houston

Browse all research sites in Texas · View every site in Houston

Sponsor Feasibility Report

Trust Score: 82/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for The University of Texas MD Anderson Cancer Center, Houston, TX?

The University of Texas MD Anderson Cancer Center, Houston, TX has a Crixeo Trust Score of 82/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has The University of Texas MD Anderson Cancer Center, Houston, TX conducted?

The University of Texas MD Anderson Cancer Center, Houston, TX has 1 clinical trials on record. Their work covers Acute Myeloid Leukaemia.

Is The University of Texas MD Anderson Cancer Center, Houston, TX accredited by Crixeo Clinical Trials?

The University of Texas MD Anderson Cancer Center, Houston, TX has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about The University of Texas MD Anderson Cancer Center, Houston, TX?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.